SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

GSK Says Efimosfermin Shows Potential to Improve Liver Fibrosis in Phase II MASH Study

Valid market news retained in the public archive without immediate LiveCast distribution.

Related stories